

Clinical Pharmacology During Pregnancy

Edited by
Donald R. Mattison



ELSEVIER

AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press in an imprint of Elsevier



Contents

List of contributors xvii

1 Introduction 1

Donald R. Mattison

2 Physiologic Changes During Pregnancy 5

Luis D. Pacheco, Maged M. Costantine, Gary D.V. Hankins

- 2.1 Physiologic changes during pregnancy 5
- 2.2 Cardiovascular system 6
- 2.3 Respiratory system 7
- 2.4 Renal system 8
- 2.5 Gastrointestinal system 10
- 2.6 Hematologic and coagulation systems 11
- 2.7 Endocrine system 12
- 2.8 Summary 14

3 Impact of Pregnancy on Maternal Pharmacokinetics of Medications 17

Mary F. Hebert

- 3.1 Introduction 17
- 3.2 Effects of pregnancy on pharmacokinetic parameters 18
 - 3.2.1 Extraction ratio 20
 - 3.2.2 Area under the concentration–time curve (AUC) 20
 - 3.2.3 Bioavailability 20
 - 3.2.4 Clearance 21
 - 3.2.5 Protein binding 22
 - 3.2.6 Organ blood flow 24
 - 3.2.7 Intrinsic clearance 25
 - 3.2.8 Metabolism 25
 - 3.2.9 Renal 30
 - 3.2.10 Volume of distribution 33
 - 3.2.11 Half-life 33
- 3.3 Summary 34

4 Medications and the Breastfeeding Mother 41

Cheston M. Berlin, Jr.

4.1	Medication use by the breastfeeding mother	41
4.2	Clinical pharmacology of drug transfer into breast milk	42
4.3	During delivery	42
4.4	General anesthesia	43
4.4.1	Volatile anesthetic agents	43
4.4.2	Intravenous anesthetic agents	43
4.4.3	A general statement	44
4.5	Epidural anesthesia	44
4.6	Galactogogues	45
4.7	Immediate postpartum period	45
4.8	Pain	46
4.8.1	Morphine	46
4.8.2	Codeine	46
4.8.3	Meperidine	47
4.8.4	Hydrocodone	47
4.9	Methadone	47
4.10	Resumption of pre-pregnancy medications	47
4.11	Psycho- and neurotropic drugs	48
4.11.1	Antidepressants, antipsychotics, anxiolytics, antiepileptics, drugs for attention deficit hyperactivity disorder	48
4.12	Drugs not to give to the nursing mother postpartum	49
4.13	Oral contraceptives (OCPs)	49
4.14	Summary	50
4.15	Where to find information	50

5 Fetal Drug Therapy 55

Erik Rytting and Mahmoud S. Ahmed

5.1	Introduction	55
5.2	Indications for fetal therapy	56
5.3	Strategies to achieve fetal drug therapy	61
5.3.1	Transplacental drug transfer	61
5.3.2	Direct fetal injection	63
5.3.3	Gene therapy	63
5.3.4	Stem cell transplantation	63
5.3.5	Nanoparticles	64
5.4	Special considerations	65
	Acknowledgments	66

6	Treating the Placenta: an Evolving Therapeutic Concept	73
	<i>Michael D. Reed and Donald R. Mattison</i>	
6.1	Introduction	73
6.2	The placenta as the therapeutic target: the past	74
6.2.1	Placental function	74
6.2.2	Placental transport mechanisms	76
6.3	The placenta: therapeutic targets	77
6.4	The placenta as a therapeutic target today	80
6.4.1	Diabetes during pregnancy	80
6.4.2	Malaria in pregnancy	81
6.4.3	HIV-1 infection in pregnancy	82
6.5	The placenta as a therapeutic target in the future	83
	Conclusions	84
7	What is Sufficient Evidence to Justify a Multicenter Phase 3 Randomized Controlled Trial in Obstetrics?	89
	<i>Gabrielle Constantin, Gabriel Shapiro, Nils Chaillet and William D. Fraser</i>	
7.1	Introduction	89
7.2	Evidence, equipoise, and the ethical considerations in deciding whether to conduct a trial	91
7.2.1	Summarizing the evidence	92
7.3	Why are failure rates so high for pregnancy drug trials compared to other therapeutic areas?	92
7.4	Role of phase 2 trials	95
7.5	How to improve success rates	96
7.6	Learning from experience – the example of antioxidants and preeclampsia	97
	Conclusions and recommendations	99
8	Ethics of Clinical Pharmacology Research in Pregnancy	103
	<i>Marvin S. Cohen</i>	
	Questions for further discussion	111

9	Pharmacogenomics in Pregnancy	113
	<i>David M. Haas and David A. Flockhart</i>	
9.1	Pharmacogenomics	113
9.2	Genetics and polymorphisms	115
9.3	Genes that influence pharmacokinetic variability	116
9.4	The current state of pharmacogenetic testing	118
9.5	Potential therapeutic areas for pharmacogenomics in pregnancy	120
9.6	Study designs and approaches to pharmacogenetics trials	122
10	Analgesics and Anti-Inflammatory, General and Local Anesthetics and Muscle Relaxants	129
	<i>Sarah Armstrong and Roshan Fernando</i>	
10.1	Introduction	129
10.2	General anesthesia	130
10.3	Inhalational anesthetics	131
10.4	Intravenous anesthetics	132
10.4.1	Thiopentone	133
10.4.2	Propofol	133
10.4.3	Ketamine	134
10.4.4	Etomidate	134
10.4.5	Benzodiazepines	134
10.4.6	Systemic opioids in pregnancy	135
10.5	Neuromuscular blocking agents	136
10.6	Regional anesthesia	137
10.6.1	Bupivacaine	138
10.6.2	Lidocaine	139
10.6.3	2-Chloroprocaine	139
10.6.4	Ropivacaine	139
10.6.5	Adjuvant opioids	140
10.6.6	Fetal effects of neuraxial opioids	141
10.7	Summary	141
11	The Management of Asthma During Pregnancy	145
	<i>Jennifer A. Namazy and Michael Schatz</i>	
11.1	Introduction	145
11.2	Effect of pregnancy on the course of asthma	145

11.3	Effect of asthma on pregnancy	147
11.4	Asthma management	148
11.5	Pharmacologic therapy	149
11.5.1	Inhaled corticosteroids	150
11.5.2	Inhaled beta-agonists	150
11.5.3	Leukotriene modifiers	152
11.5.4	Cromolyn and theophylline	152
11.5.5	Oral corticosteroids	152
	Conclusion	153

12 Updated Guidelines for the Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum 157

Caroline Maltepe, Rachel Gow and Gideon Koren

12.1	Introduction	157
12.2	Hyperemesis gravidarum	158
12.3	Etiology and risk factors	159
12.4	Differential diagnosis	159
12.5	Management of NVP and HG	160
12.5.1	Dietary and lifestyle approaches	161
12.5.2	Treatment for acidity and indigestion	162
12.5.3	Non-pharmacological approaches	162
12.5.4	Pharmacological approaches	162
12.5.5	Management of HG	165
	Conclusion	167

13 Clinical Pharmacology of Anti-Infectives During Pregnancy 173

Brookie M. Best

13.1	Antibacterial therapy	174
13.2	Antifungal therapy	180
13.3	Malaria	181
13.4	Tuberculosis	183
13.5	HIV	184
13.6	Antivirals	189
13.7	Parasitic infections	191

14	Chemotherapy in Pregnancy	201
	<i>Caroline D. Lynch, Men-Jean Lee and Giuseppe Del Priore</i>	
14.1	Introduction	201
14.2	Overview of chemotherapeutic agents	202
14.2.1	Antimetabolites	202
14.3	Alkylating agents	204
14.4	Anthracyclines	205
14.5	Plant alkaloids	206
14.5.1	Taxanes	207
14.5.2	Hormonal agents	207
14.6	Targeted therapies	208
14.7	Other agents	209
14.8	Treatment of specific cancers	209
14.9	Breast cancer	210
14.10	Lymphoma	210
14.11	Leukemia	211
14.12	Ovarian cancer	211
14.13	Future fertility	212
14.14	Pharmacokinetics in pregnancy	212
15	Substance Use Disorders	217
	<i>James J. Nocon</i>	
15.1	Introduction	217
15.2	Substance use disorders defined	218
15.3	Addiction defined as a disease of the brain	219
15.4	The good news: the brain can recover	220
15.5	Pregnancy enhances recovery	221
15.6	Addiction in women and pregnancy	222
15.7	Psychiatric co-morbidity	223
15.8	Substances used	224
15.8.1	Alcohol	225
15.8.2	Tobacco; nicotine	226
15.8.3	Opiates and opioids	227
15.8.4	Fentanyl	235
15.8.5	Benzodiaepines	235
15.8.6	Marijuana; THC	235
15.8.7	Cocaine	236
15.8.8	Stimulants: amphetamine, methamphetamine; methylphenidate; ephedra; khat	237

15.8.9	Hallucinogens: lysergic acid diethylamide and phencyclidine	238
15.8.10	Club drugs: MDMA; flunitrazepam; gamma-hydroxybuterate; ketamine	238
15.9	Screening and detection	239
15.10	The role of urine and meconium testing	240
15.11	Brief office screening strategies	242
15.12	Brief office interventions	245
15.13	Long-term care and maintenance	246
	Conclusion	247

16 **Diabetes in Pregnancy** **257**

Maisa N. Feghali, Rita W. Driggers, Menachem Miodovnik and Jason G. Umans

16.1	Introduction	257
16.2	Epidemiology	258
16.3	Classification	258
16.4	Gestational diabetes	259
16.5	Diabetes management in pregnancy	260
16.5.1	Nutritional goals and exercise	260
16.5.2	Glucose monitoring and glycemic control	260
16.5.3	Insulin therapy	261
16.5.4	Oral hypoglycemics	264
16.5.5	Postpartum metabolic management	268
	Conclusion	268

17 **Cardiovascular Medications in Pregnancy** **275**

Thomas R. Easterling

17.1	Introduction	275
17.2	Cardiovascular changes in pregnancy	277
17.3	Cardiovascular diseases in pregnancy	279
17.4	Pharmacodynamics of hemodynamically active drugs in pregnancy	281
17.5	Fetal pharmacodynamic response to hemodynamically active drugs	284
17.6	Direct fetal effects of hemodynamically active drugs	286
17.7	Pharmacokinetic changes in hemodynamically active drugs in pregnancy	287
	Key points	291

18	Antidepressants in Pregnancy	295
	<i>Elizabeth M. LaRusso and Marlene P. Freeman</i>	
18.1	Introduction	295
18.2	Effects of untreated perinatal depression on women and children	296
18.3	Approach to treatment	297
18.4	Potential risks of selective serotonin reuptake inhibitor (SSRI) use during pregnancy	299
18.4.1	Obstetric outcomes	300
18.4.2	Congenital malformations	300
18.4.3	Persistent pulmonary hypertension of the newborn (PPHN)	301
18.4.4	Poor neonatal adaptation	301
18.4.5	Neurodevelopmental outcomes	302
18.5	Potential risks of non-SSRI antidepressant use during pregnancy	302
18.6	Potential risks of older antidepressant use during pregnancy	303
18.7	Anxiety	303
18.8	Summary	304
19	Uterine Contraction Agents and Tocolytics	307
	<i>Courtney D. Cuppett and Steve N. Caritis</i>	
19.1	Introduction	307
19.2	Uterine contraction agents (uterotonics)	307
19.2.1	Pitocin (oxytocin)	308
19.2.2	Methergine (methylergonovine)	310
19.2.3	Prostaglandins	311
19.2.4	Uterotonics summary	316
19.3	Uterine relaxation agents (tocolytics)	316
19.3.1	Magnesium sulfate (MgSO ₄)	319
19.3.2	β -Adrenergic-receptor agonists	319
19.3.3	Nitric oxide donors	321
19.3.4	Calcium channel blockers	321
19.3.5	Cyclooxygenase inhibitors (COX inhibitors)	322
19.3.6	Oxytocin receptor antagonists (atosiban)	324
19.3.7	Tocolytics summary	325

20	Antenatal Thyroid Disease and Pharmacotherapy in Pregnancy	331
	<i>Shannon M. Clark and Gary D.V. Hankins</i>	
20.1	Thyroid function and physiology in pregnancy	331
20.2	Hyperthyroidism in pregnancy	333
20.3	Pharmacotherapy with thionamides in pregnancy	336
20.4	Hypothyroidism in pregnancy	339
20.5	Pharmacotherapy with levothyroxine in pregnancy	342
20.6	Summary	344
21	Dermatological Medications and Local Therapeutics	349
	<i>Maria-Magdalena Roth and Caius Solovan</i>	
21.1	Introduction	349
21.2	Acne	350
	21.2.1 Systemic treatment for acne	350
	21.2.2 Local treatment for acne	351
21.3	Psoriasis	352
	21.3.1 Systemic treatment for psoriasis	352
	21.3.2 Local treatment for psoriasis	353
	21.3.3 Phototherapy	354
21.4	Bacterial infections	354
	21.4.1 Systemic treatment of bacterial infections	354
	21.4.2 Local treatment of bacterial infections	355
21.5	Viral infections	356
	21.5.1 Systemic treatment of viral infections	356
	21.5.2 Local treatment of viral infections	356
21.6	Fungal infections	356
	21.6.1 Systemic treatment for fungal infections	356
	21.6.2 Local treatment for fungal infections	357
21.7	Parasitic infections	357
	21.7.1 Systemic and local treatment for parasitic infections	357
21.8	Antipruritics	358
	21.8.1 Systemic antipruritics	358
	21.8.2 Local antipruritics	359
21.9	Glucocorticosteroids	360
	21.9.1 Systemic glucocorticosteroids	360
	21.9.2 Local glucocorticosteroids	360
21.10	Immunomodulators/immunosuppressive therapy	361

21.11	Analgesics	361
21.11.1	Systemic analgesics	361
21.11.2	Local analgesics (Anesthesia)	362
21.12	Antiseptics (disinfectants)	363

22 Vitamins, Minerals, Trace Elements, and Dietary Supplements 367

Jean-Jacques Dugoua

22.1	Introduction	367
22.2	First trimester	369
22.2.1	Vitamin B ₆ (pyridoxine)	369
22.2.2	Vitamin B ₉ (folic acid)	371
22.2.3	Vitamin A	374
22.2.4	Vitamin E	375
22.2.5	Calcium	375
22.3	Second trimester	376
22.3.1	Calcium	376
22.3.2	Vitamins C, E, and zinc	377
22.3.3	Chromium	377
22.3.4	Coenzyme Q10 (CoQ10)	377
22.4	Third trimester	378
22.4.1	Castor oil (<i>Ricinus communis</i>)	378

23 Herbs and Alternative Remedies 383

Henry M. Hess

23.1	Herbal teas frequently used during pregnancy	384
23.2	Essential oils used as aromatherapy during pregnancy	385
23.3	Herbs used as capsules or dried extracts	386
23.3.1	Ginger	386
23.3.2	Cranberry	386
23.3.3	Echinacea	387
23.3.4	St. John's wort	387
23.3.5	Valerian	388
23.3.6	Milk thistle/silymarin	388
23.3.7	Senna	389
23.3.8	Horse chestnut	389
23.4	Herbal topical preparations used in pregnancy	390
23.4.1	Aloe vera gel	390
23.4.2	Horse chestnut	390

23.5	Non-herbal supplements used in pregnancy	390
23.5.1	Fish oils	390
23.5.2	Probiotics	391
23.6	Herbs used to induce labor	391
23.7	Acupuncture and acupressure therapy in pregnancy	392
23.8	Meditation and hypnosis in pregnancy	392

24 **Envenomations and Antivenoms During Pregnancy** **395**

Steffen A. Brown and William F. Rayburn

24.1	General principles about envenomation	395
24.2	Snake bites	398
24.2.1	Management during pregnancy	398
24.2.2	Reports during pregnancy	399
24.3	Spider bites	400
24.3.1	Management during pregnancy	401
24.3.2	Reports during pregnancy	402
24.4	Scorpion stings	402
24.4.1	Management during pregnancy	403
24.4.2	Reports during pregnancy	404
24.5	Hymenoptera	404
24.5.1	Winged hymenoptera	405
24.5.2	Imported fire ants	405
24.5.3	Management during pregnancy	406
24.5.4	Reports during pregnancy	406
24.6	Jellyfish	407
24.6.1	Management during pregnancy	408
24.6.2	Reports during pregnancy	408
24.7	Antivenom use during pregnancy	409
	Conclusions	410

25 **Gastrointestinal Disorders** **415**

Noel Lee, Veronika Gagovic and Sumona Saha

25.1	Gastroesophageal reflux disease	415
25.1.1	Treatment	416
25.1.2	Antacids	416
25.1.3	Sucralfate	417
25.1.4	Promotility agents	417
25.1.5	H ₂ -Receptor antagonists	417
25.1.6	Proton pump inhibitors	418

25.2	Peptic ulcer disease	420
25.2.1	Treatment	420
25.3	Constipation	421
25.3.1	Treatment	421
25.4	Diarrhea	424
25.4.1	Treatment	424
25.5	Abdominal pain	424
25.6	Gastrointestinal infections	425
25.7	Inflammatory bowel disease	429
25.7.1	Treatment	429
25.8	Hepatitis B	432
25.8.1	Treatment	434
25.9	Hepatitis C	434
25.9.1	Treatment	435
25.10	Wilson's disease	435
25.10.1	Treatment	435
25.11	Autoimmune hepatitis	436
25.12	Intrahepatic cholestasis of pregnancy	436
25.13	Primary biliary cirrhosis and primary sclerosing cholangitis	437